Mankind Pharma Completes Interest Payment and Full Redemption of Non-Convertible Debentures Worth ₹12,50,00,00,000

Mankind Pharma Limited has successfully completed the payment of interest and full redemption of its Non-Convertible Debentures (NCDs) on April 16, 2026, as communicated to BSE Limited under Regulation 57(1) of the SEBI Listing Regulations.

Interest Payment Details

The company paid interest across three different ISIN series with a total gross amount of ₹1,989,534,267. All payments were made on the scheduled due date of April 16, 2026, with the record date set as April 1, 2026.

ISIN Series	Issue Size (₹)	Gross Interest Amount (₹)	Net Interest Amount (₹)
INE634S07017	12,50,00,00,000	498,006,855	477,488,970
INE634S07025	12,50,00,00,000	498,006,853	497,010,839
INE634S07033	25,00,00,00,000	993,520,559	992,693,949

All three series follow a half-yearly payment frequency, with the last interest payment made on October 16, 2025. The company reported no delays or issues in the payment process.

NCD Redemption Completion

Mankind Pharma completed the full redemption of NCDs under ISIN INE634S07017 upon maturity. The redemption was executed on the scheduled due date without any delays.

Parameter	Details
Redemption Type	Full
Reason for Redemption	Maturity
Quantity Redeemed	1,25,000 NCDs
Amount Redeemed	₹12,50,00,00,000
Outstanding Amount	₹0
Redemption Date	April 16, 2026

Regulatory Compliance

The payment and redemption activities were conducted in accordance with SEBI Master Circular No. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/000000137 dated October 15, 2025. The company has uploaded all relevant information on its official website at www.mankindpharma.com for stakeholder access.

The successful completion of both interest payments and NCD redemption demonstrates Mankind Pharma's commitment to timely debt servicing and regulatory compliance. The company secretary and compliance officer, Hitesh Kumar Jain, signed the intimation digitally on April 16, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.11%	+7.75%	+17.64%	-7.49%	-10.93%	+59.42%

Mankind Pharma Ltd. witnessed a substantial block trade on the National Stock Exchange (NSE), with the transaction valued at Rs. 44.67 crores. The large-scale trade reflects significant institutional activity in the pharmaceutical company's shares.

Block Trade Details

The NSE block trade involved key parameters that highlight the scale of the transaction:

Parameter:	Details
Total Value:	Rs. 44.67 crores
Number of Shares:	~210,721 shares
Price Per Share:	Rs. 2,120.00
Exchange:	National Stock Exchange (NSE)

Market Implications

Block trades represent off-market transactions typically executed between institutional investors, mutual funds, or other large market participants. These transactions are conducted at predetermined prices and volumes, often indicating significant portfolio adjustments or strategic investment decisions.

The execution price of Rs. 2,120.00 per share for this particular transaction provides a reference point for the stock's institutional valuation. Such large-volume trades can influence market sentiment and provide insights into institutional investor confidence in Mankind Pharma's business prospects.

Transaction Significance

The Rs. 44.67 crore transaction represents a notable movement in Mankind Pharma's stock, involving over 210,000 shares. Block trades of this magnitude typically occur when institutional investors are making substantial portfolio changes or when there are significant corporate developments warranting large-scale transactions.

For market participants and retail investors, monitoring such block trades can provide valuable insights into institutional investor behavior and potential shifts in the stock's ownership structure.